LUMO — Lumos Pharma Income Statement
0.000.00%
Last trade - 00:00- $37.41m
- $23.89m
- $2.05m
Annual income statement for Lumos Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.936 | 0.168 | 0.23 | 1.52 | 2.05 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 46.1 | 26.5 | 31.6 | 33.6 | 38.7 |
| Operating Profit | -45.1 | -26.3 | -31.3 | -32 | -36.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -43 | -19.6 | -31.1 | -31.1 | -34.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -43 | -5.66 | -30.4 | -31.1 | -34 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43 | -5.66 | -30.4 | -31.1 | -34 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43 | -6.31 | -30.4 | -31.1 | -34 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.44 | -0.932 | -3.65 | -3.71 | -4.18 |